Shield Therapeutics (LON:STX) Shares Pass Below 50 Day Moving Average – Time to Sell?

Shield Therapeutics plc (LON:STX)’s stock price crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of GBX 10.65 and traded as low as GBX 10. Shield Therapeutics shares last traded at GBX 10.60, with a volume of 1,701,659 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Peel Hunt reissued a “buy” rating and issued a GBX 15 target price on shares of Shield Therapeutics in a research note on Friday, November 7th. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, Shield Therapeutics currently has a consensus rating of “Buy” and a consensus target price of GBX 15.

Shield Therapeutics Trading Up 1.0%

The firm has a market capitalization of £113.21 million, a PE ratio of -5.30 and a beta of 1.42. The firm has a 50 day simple moving average of GBX 10.65 and a 200 day simple moving average of GBX 8.48. The company has a current ratio of 1.05, a quick ratio of 2.16 and a debt-to-equity ratio of 3,691.50.

About Shield Therapeutics

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.